间充质干细胞
系统性红斑狼疮
四氯化碳
B细胞
骨髓
免疫学
狼疮性肾炎
干细胞
体内
医学
癌症研究
炎症
生物
趋化因子
细胞生物学
抗体
内科学
疾病
生物技术
作者
Nan Che,Xia Li,Lu Zhang,Rui Li,Haifeng Chen,Xiang Gao,Songtao Shi,Wanjun Chen,Lingyun Sun
出处
期刊:Journal of Immunology
[The American Association of Immunologists]
日期:2014-11-15
卷期号:193 (10): 5306-5314
被引量:70
标识
DOI:10.4049/jimmunol.1400036
摘要
Abstract Mesenchymal stem cells (MSC) from healthy human and normal mice can inhibit normal B cell proliferation, differentiation, and Ab secretion in vitro. However, it remains unknown whether MSC from lupus-like mice and patients with systemic lupus erythematosus (SLE) exhibit the same immunoregulatory activity as normal MSC for B cell inhibition and, if not, what the underlying molecular mechanism would be. In this study, we showed that bone marrow–derived MSCs from lupus-like mice and SLE patients had an impairment in suppressing normal B cell proliferation and differentiation, which was caused by the reduction of CCL2 levels. Knockdown of CCL2 in normal MSC damaged their suppressive capacity for B cells. Conversely, overexpression of CCL2 in lupus MSCs restored their immunoregulatory ability for B cells in vitro and ameliorated the pathology of lupus nephritis and serological changes in MRL/lpr mice in vivo. Mechanistically, MSC-mediated B cell inhibition was dependent on matrix metalloproteinase proteolytic processing of CCL2. These findings reveal a novel function of CCL2 in B cell regulation by MSCs and suggest that CCL2 manipulation on MSCs may serve as a potential pathway for developing the more effective MSC-based therapy in autoimmune diseases associated with B cell activation, such as SLE.
科研通智能强力驱动
Strongly Powered by AbleSci AI